Clinical Manifestations and Diagnostic Challenges of Cytomegalovirus Infection in HIV Patients: A Case Series Study from Morocco
Article Sidebar
Main Article Content
Abstract
Cytomegalovirus (CMV) infection is a major cause of morbidity in immunocompromised patients, particularly those living with Human Immunodeficiency Virus (HIV). This study describes the clinical manifestations, diagnostic approaches, and therapeutic challenges of CMV infection in HIV patients in Morocco. A descriptive retrospective study was conducted on seventeen (17) HIV patients with CMV infection, diagnosed by real-time Polymerase Chain Reaction (PCR). Clinical, virological (HIV and CMV viral load, CD4 count), and therapeutic data were subsequently analysed. The mean age was 43 ± 10.7 years, with male predominance (94.1%). Digestive manifestations (29.4%) were the most frequent, followed by respiratory and neurological involvement (17.6% each). The mean CD4 count was 65.4 ± 56.2 cells/mm³. The mean CMV viral load was 2.39 ± 0.74 Log and the mean HIV viral load was 4.10 ± 1.55 Log. Antiviral therapy for CMV could not be initiated in 47% of patients due to its unavailability. The outcome was favorable in 88.2% of patients, with a mortality rate of 11.8%. In conclusion; CMV infection in HIV patients in Morocco occurs in the context of severe immunosuppression and presents with a varied clinical spectrum, dominated by digestive pathologies. Real-time PCR remains crucial for diagnosis. The unavailability of antiviral drugs constitutes a major challenge for management, highlighting the need to improve access to treatments in resource-limited settings.
Article Details
Copyright (c) 2025 Ouassas I, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
1. Segondy M. Cytomégalovirus humain. In: EMC, Biologie clinique. Paris: Elsevier Masson SAS; 2009. p. 90-55-0035.
2. Meyohas MC. Stratégies de prévention des infections à CMV chez les sujets immunodéprimés. Rev Fr Lab. 2002;(345):35-40. Available from: https://doi.org/10.1016/S0338-9898(02)80263-3
3. Steininger C, Puchhammer-Stockl E, Popow-Kraupp T. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J Clin Virol. 2006;37(1):1-9.Available from: https://doi.org/10.1016/j.jcv.2006.03.005
4. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288-97. https://doi.org/10.1002/path.4437
5. Tagarro A, Del Valle R, Dominguez-Rodríguez S, et al. Growth patterns in children with congenital cytomegalovirus infection. Pediatr Infect Dis J. 2019;38(12):1230-5. Available from: https://doi.org/10.1097/inf.0000000000002483
6. Salmon-Ceron D. Manifestations cliniques de l'infection à cytomégalovirus au cours du SIDA. In: Nicolas JC, editor. Cytomégalovirus. Paris: Elsevier Collection MediBio; 2002. p. 121-9.
7. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. Arch Intern Med. 1998;158(9):957-69. Available from: https://doi.org/10.1001/archinte.158.9.957
8. Springer KL, Weinberg A. Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity. J Antimicrob Chemother. 2004;54(3):582-6. Available from: https://doi.org/10.1093/jac/dkh396
9. Imbert-Marcille BM. Histoire naturelle des infections à cytomégalovirus. Med Ther. 2001;7:577-84.
10. Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. 3rd ed. Washington (DC): ASM Press; 2009. p. 1408.
11. Jabs DA. Cytomegalovirus retinitis and the acquired immunodeficiency syndrome-bench to bedside: LXVII Edward Jackson memorial lecture. Am J Ophthalmol. 2011;151(2):212-41. Available from: https://www.ajo.com/article/S0002-9394(10)00817-2/pdf
12. Ford N, Shubber Z, Saranchuk P, Pathai S, Durier N, O'Brien DP, et al. Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review. Clin Infect Dis. 2013;57(9):1351-61. Available from: https://doi.org/10.1093/cid/cit494
13. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. Arch Intern Med. 1998;158(9):957-69. Available from: https://doi.org/10.1001/archinte.158.9.957
14. Pulakhandam U, Dincsoy HP. Cytomegaloviral adrenalitis and adrenal insufficiency in AIDS. Am J Clin Pathol. 1990;93(5):651-6. Available from: https://doi.org/10.1093/ajcp/93.5.651
15. Dioverti MV, Razonable RR. Cytomegalovirus. Microbiol Spectr. 2016;4(2):10.1128/microbiolspec.DMIH2-0022-2015. Available from: https://doi.org/10.1128/microbiolspec.dmih2-0022-2015
16. Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol. 2002;40(3):746-52. Available from: https://doi.org/10.1128/jcm.40.3.746-752.2002
17. Sangavi SK, Abu-Elmagd K, Keightley MC, St George K, Lewandowski K, Boes SS, et al. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. J Clin Virol. 2008;42(4):335-42. Available from: https://doi.org/10.1016/j.jcv.2008.03.031
18. Larsson S, Söderberg-Naucler C, Wang FZ, Moller E. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transfusion. 1998;38(3):271-8. Available from: https://doi.org/10.1046/j.1537-2995.1998.38398222871.x
19. Paya CV, Smith TF, Ludwig J, Hermans PE. Rapid shell vial culture and tissue histology compared with serology for the rapid diagnosis of cytomegalovirus infection in liver transplantation. Mayo Clin Proc. 1989;64(6):670-5. Available from: https://doi.org/10.1016/s0025-6196(12)65346-4
20. Paya CV, Holley KE, Wiesner RH, Balasubramaniam K, Smith TF, Espy MJ, et al. Early diagnosis of cytomegalovirus hepatitis in liver transplant recipients: role of immunostaining, DNA hybridization, and culture of hepatic tissue. Hepatology. 1990;12(1):119-26. Available from: https://doi.org/10.1002/hep.1840120119
21. Lautenschlager I, Halme L, Höckerstedt K, Krogerus L, Taskinen E. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis. 2006;8(1):21-30. Available from: https://doi.org/10.1111/j.1399-3062.2006.00122.x
22. St George K, Rinaldo CR Jr. Comparison of cytomegalovirus antigenemia and culture assays in patients on and off antiviral therapy. J Med Virol. 1999;59(1):91-7. Available from: https://pubmed.ncbi.nlm.nih.gov/10440814
23. Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006;71(2-3):154-63. Available from: https://doi.org/10.1016/j.antiviral.2006.05.002
24. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A. 2000;97(14):8039-44. Available from: https://doi.org/10.1073/pnas.140123497
25. McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs. 2001;61(8):1153-83. Available from: https://doi.org/10.2165/00003495-200161080-00016